Posted by Michael Wonder on 17 Jun 2021
The FDA is in desperate need of some soul-searching
17 June 2021 - Ordinarily, the approval of a new drug for a dreaded disease affecting millions of Americans would be a cause for celebration.
But aducanumab, which the FDA approved last week to treat Alzheimer’s disease, is no ordinary drug.
It encapsulates everything that ails the regulation of the pharmaceutical industry and is a grim reminder of the soul-searching about the FDA’s integrity that’s desperately needed.
